HEUKING advises BIOWEG on its Extension of Series A Financing Round to 30 million Euro

HEUKING advised BIOWEG GmbH, an industrial biotechnology start-up based in Quakenbrück, on the extension of its Series A financing round. As part of the transaction, BIOWEG secured 14 million Euro extension of its Series A financing from Rabobank Ventures as well as 10.3 million Euro in EU funding under the "Produktives.NRW" grant competition (ERDF/JTF Program for North Rhine-Westphalia 2021–2027). The total Series A round now stands at 30 million Euro.

BIOWEG converts agricultural and food industry side streams into high-performance, biodegradable ingredients designed to replace intentionally added microplastics in agriculture, personal care and home care. With the new capital, BIOWEG plans to build Europe's largest bacterial cellulose production plant in North Rhine-Westphalia. Construction is scheduled to begin in Q4 2026, with the first commercial volumes expected in 2028.

The HEUKING team led by Ilona Schütz, Dr. Patrick Müller, LL.M. and Dr. Oliver Böttcher advised BIOWEG GmbH on the extension of the Series A financing round. Dr. Ute Jasper and Johannes Baumann advised on the implementation of subsidy law requirements in connection with the EU/ERDF-JTF funding.

Counsel to BIOWEG GmbH
HEUKING:
Ilona Schütz (Lead, Venture Capital, Düsseldorf)
Dr. Patrick Müller, LL.M. (University of the West of England, Bristol), (Venture Capital, Düsseldorf)
Dr. Oliver Böttcher (Venture Capital, Cologne)
Dr. Ute Jasper (Public Sector and Procurement, Düsseldorf)
Johannes Baumann (Public Sector and Procurement, Düsseldorf)